There are 2789 resources available
710P - Comprehensive genomic profiling (CGP) of small cell neuroendocrine carcinoma of the bladder (NEBC)
Presenter: Andrea Necchi
Session: ePoster Display
711P - Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Presenter: Cedric Pobel
Session: ePoster Display
712P - Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor
Presenter: Roman Sosnowski
Session: ePoster Display
713P - Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial
Presenter: Natacha Naoun
Session: ePoster Display
714P - Prognostic factors in stage I seminoma: Data from the phase III, randomised TRial of Imaging and Surveillance in Seminoma Testis (TRISST)
Presenter: Elizabeth James
Session: ePoster Display
715P - Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program
Presenter: Damien Pouessel
Session: ePoster Display
716TiP - IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy
Presenter: Thomas Powles
Session: ePoster Display
718TiP - KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
Presenter: Shahrokh F. Shariat
Session: ePoster Display
719TiP - SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy
Presenter: Michiel van der Heijden
Session: ePoster Display